Community-acquired pneumonia (CAP), also known as community-acquired bacterial pneumonia (CABP), is an infection of the lungs that is acquired outside of the hospital setting. Lower respiratory infections including CAP are the leading cause of death from infectious disease in the world. In the US, there were 1.3 million emergency department visits and 49,157 deaths attributed to pneumonia in 2017. When combined with influenza, pneumonia was the eighth leading cause of death in the US. In the elderly, CAP has a higher burden of hospitalization and total cost than heart attack, stroke, and fractures combined. It is linked to 1.5 million hospitalizations in adults each year, with an estimated mortality rate of 6.5% during hospitalization.6 In October of 2019, the American Thoracic Society, along with the Infectious Diseases Society of America, published an updated guideline on the diagnosis and treatment of adults with CAP.This guideline is the long-awaited update to the 2007 version published by the same groups. This update does not provide recommendations for managing foreign travelers or patients who are immunocompromised (eg, patients receiving cancer chemotherapy, bone marrow transplant recipients, HIV patients, etc.). Notable changes to the guideline include the removal of the healthcare-associated pneumonia category, the use of empiric amoxicillin monotherapy for outpatients with no coexisting conditions (eg, chronic lung, heart, liver, or kidney disease; diabetes, asplenia, malignancy, or alcoholism), and the use of macrolide monotherapy only if local resistance rates are less than 25%. This issue summarizes the causes, risk factors, and current treatment recommendations for CAP in adults. The 2019 guideline was released before the pandemic caused by severe acute respiratory syndrome coronavirus (SARSCoV-2). The guideline and this issue do not include information on managing CAP in patients with coronavirus disease 2019 (COVID-19).
- Pharmacists, Nurse Practitioners, Clinical Nurse Specialists, and Registered Nurses
This CE activity was developed by The Rx Consultant, a publication of Continuing Education Network, Inc.
CE activities for Pharmacists and Pharmacy Technicians:
This continuing education (CE) activity meets the requirements of all state boards of pharmacy for approved continuing education hours. CE credit is automatically reported to CPE Monitor.
CE activities for Nurse Practitioners and Clinical Nurse Specialists:
This continuing education activity meets the requirements of:
The American Nurses Credentialing Center (ANCC) for formally approved continuing education (CE) hours, and CE hours of pharmacotherapeutics.
The American Academy of Nurse Practitioners Certification Program (AANPCP) for acceptable, accredited CE.
This is a pharmacotherapeutics/pharmacology CE activity.
Continuing Education Network, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Requirements for CE Credit
- Describe the most common pathogens implicated in CAP, along with risk factors for resistant organisms.
- Discuss the treatment options for CAP, taking into consideration coexisting conditions and severity of illness.
- Counsel patients on potential side effects of the antibiotics recommended for treatment and strategies for the prevention of CAP.
Ann Lloyd, PharmD, BCPS-AQ ID, BCIDP
Brief Bio : Ann Lloyd, PharmD, BCPS-AQ ID, BCIDP is a Clinical Associate Professor in the Department of Pharmacy: Clinical and Administrative Sciences at the University of Oklahoma College of Pharmacy. She is also a Clinical Pharmacy Specialist in Infectious Diseases and PYG2 Infectious Diseases Pharmacy Residency Program Director at Saint Francis Hospital in Tulsa, Oklahoma.
Release Date: Sep 22, 2020
Credit Expiration Date: Sep 22, 2023
The CE Activity developed by The Rx Consultant